1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
a)
|
Name
|
Ms E Walmsley
|
|
b)
|
Position/status
|
Chief
Executive Officer
|
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
|
b)
|
Nature
of the transaction
|
Increase in notional interest in Ordinary Shares following the
re-investment of dividends paid to shareholders on 12 October 2017
on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus
Plan.
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
£15.275
|
75.595
(personal contribution)
|
||
£15.275
|
187.204
(personal contribution)
|
||
£15.275
|
203.821
(personal contribution)
|
||
£15.275
|
75.595
(personal contribution)
|
||
£15.275
|
187.191
(personal contribution)
|
||
£15.275
|
203.809
(personal contribution)
|
||
£15.275
|
75.595
(matching shares)
|
||
£15.275
|
187.204
(matching shares)
|
||
£15.275
|
203.821
(matching shares)
|
||
£15.275
|
75.595
(matching shares)
|
||
£15.275
|
187.191
(matching shares)
|
||
£15.275
|
203.809
(matching shares)
|
||
d)
|
Aggregated
information
Aggregated
volume
Price
|
1,866.43
£15.275
|
|
e)
|
Date
of the transaction
|
2017-10-12
|
|
f)
|
Place
of the transaction
|
n/a
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
a)
|
Name
|
Mr R G Connor
|
|
b)
|
Position/status
|
President, Global Manufacturing & Supply
|
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
|
b)
|
Nature
of the transaction
|
Increase in notional interest in Ordinary Shares following the
re-investment of dividends paid to shareholders on 12 October 2017
on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus
Plan.
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
£15.275
|
55.361
(personal contribution)
|
||
£15.275
|
127.190
(personal contribution)
|
||
£15.275
|
106.128
(personal contribution)
|
||
£15.275
|
55.361
(personal contribution)
|
||
£15.275
|
106.115
(personal contribution)
|
||
£15.275
|
55.361
(matching shares)
|
||
£15.275
|
127.19
(matching shares)
|
||
£15.275
|
106.128
(matching shares)
|
||
£15.275
|
55.361
(matching shares)
|
||
£15.275
|
106.115
(matching contribution)
|
||
d)
|
Aggregated
information
Aggregated
volume
Price
|
900.310
£15.275
|
|
e)
|
Date
of the transaction
|
2017-10-12
|
|
f)
|
Place
of the transaction
|
n/a
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
a)
|
Name
|
Mr L Debruyne
|
|
b)
|
Position/status
|
President, Global Vaccines
|
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
|
b)
|
Nature
of the transaction
|
Increase in notional interest in Ordinary Shares following the
re-investment of dividends paid to shareholders on 12 October2017
on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus
Plan.
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
£15.275
|
178.377
(personal contribution)
|
||
£15.275
|
178.365
(personal contribution)
|
||
£15.275
|
178.377
(matching shares)
|
||
£15.275
|
178.365
(matching shares)
|
||
d)
|
Aggregated
information
Aggregated
volume
Price
|
713.484
£15.275
|
|
e)
|
Date
of the transaction
|
2017-10-12
|
|
f)
|
Place
of the transaction
|
n/a
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
a)
|
Name
|
Mr S Dingemans
|
|
b)
|
Position/status
|
Chief Financial Officer
|
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
|
b)
|
Nature
of the transaction
|
Increase in notional interest in Ordinary Shares following the
re-investment of dividends paid to shareholders on 12 October 2017
on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus
Plan.
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
£15.275
|
105.590
(personal contribution)
|
||
£15.275
|
247.218
(personal contribution)
|
||
£15.275
|
185.166
(personal contribution)
|
||
£15.275
|
105.576
(personal contribution)
|
||
£15.275
|
247.205
(personal contribution)
|
||
£15.275
|
185.166
(personal contribution)
|
||
£15.275
|
105.590
(matching shares)
|
||
£15.275
|
247.218
(matching shares)
|
||
£15.275
|
185.166
(matching shares)
|
||
£15.275
|
105.576
(matching shares)
|
||
£15.275
|
247.205
(matching shares)
|
||
£15.275
|
185.166
(matching shares)
|
||
d)
|
Aggregated
information
Aggregated
volume
Price
|
2,151.842
£15.275
|
|
e)
|
Date
of the transaction
|
2017-10-12
|
|
f)
|
Place
of the transaction
|
n/a
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
a)
|
Name
|
Mr N Hirons
|
|
b)
|
Position/status
|
SVP, Global Ethics & Compliance
|
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
|
b)
|
Nature
of the transaction
|
Increase in notional interest in Ordinary Shares following the
re-investment of dividends paid to shareholders on 12 October2017
on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus
Plan.
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
£15.275
|
38.762
(personal contribution)
|
||
£15.275
|
91.407
(personal contribution)
|
||
£15.275
|
67.081
(personal contribution)
|
||
£15.275
|
38.762
(personal contribution)
|
||
£15.275
|
91.407
(personal contribution)
|
||
£15.275
|
67.068
(personal contribution)
|
||
£15.275
|
38.762
(matching shares)
|
||
£15.275
|
91.407
(matching shares)
|
||
£15.275
|
67.081
(matching shares)
|
||
£15.275
|
38.762
(matching shares)
|
||
£15.275
|
91.407
(matching shares)
|
||
£15.275
|
67.068
(matching shares)
|
||
d)
|
Aggregated
information
Aggregated
volume
Price
|
788.974
£15.275
|
|
e)
|
Date
of the transaction
|
2017-10-12
|
|
f)
|
Place
of the transaction
|
n/a
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
a)
|
Name
|
Mr B McNamara
|
|
b)
|
Position/status
|
CEO, GSK Consumer Healthcare
|
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
a)
|
Description
of the financial instrument
|
American Depositary Shares ('ADSs')
ISIN:
US37733W1053
|
|
b)
|
Nature
of the transaction
|
Increase in notional interest in ADSs following the re-investment
of dividends paid to shareholders on 12 October 2017 on ADSs held
in the Company's 2009 Deferred Annual Bonus Plan.
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
$41.020
|
75.963
(personal contribution)
|
||
$41.020
|
75.963
(matching shares)
|
||
d)
|
Aggregated
information
Aggregated
volume
Price
|
151.926
$41.020
|
|
e)
|
Date
of the transaction
|
2017-10-12
|
|
f)
|
Place
of the transaction
|
n/a
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
a)
|
Name
|
Mr D S Redfern
|
|
b)
|
Position/status
|
Chief Strategy Officer
|
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
|
b)
|
Nature
of the transaction
|
Increase in notional interest in Ordinary Shares following the
re-investment of dividends paid to shareholders on 12 October 2017
on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus
Plan.
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
£15.275
|
62.115
(personal contribution)
|
||
£15.275
|
116.331
(personal contribution)
|
||
£15.275
|
84.422
(personal contribution)
|
||
£15.275
|
62.115
(personal contribution)
|
||
£15.275
|
116.331
(personal contribution)
|
||
£15.275
|
84.409
(personal contribution)
|
||
£15.275
|
62.115
(matching shares)
|
||
£15.275
|
116.331
(matching shares)
|
||
£15.275
|
84.422
(matching shares)
|
||
£15.275
|
62.115
(matching shares)
|
||
£15.275
|
116.331
(matching shares)
|
||
£15.275
|
84.409
(matching shares)
|
||
d)
|
Aggregated
information
Aggregated
volume
Price
|
1,051.446
£15.275
|
|
e)
|
Date
of the transaction
|
2017-10-12
|
|
f)
|
Place
of the transaction
|
n/a
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
a)
|
Name
|
Ms C Thomas
|
|
b)
|
Position/status
|
SVP, Human Resources
|
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
|
b)
|
Nature
of the transaction
|
Increase in notional interest in Ordinary Shares following the
re-investment of dividends paid to shareholders on 12 October 2017
on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus
Plan.
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
£15.275
|
83.607
(personal contribution)
|
||
£15.275
|
170.189
(personal contribution)
|
||
£15.275
|
127.067
(personal contribution)
|
||
£15.275
|
83.594
(personal contribution)
|
||
£15.275
|
170.189
(personal contribution)
|
||
£15.275
|
127.067
(personal contribution)
|
||
£15.275
|
83.607
(matching shares)
|
||
£15.275
|
170.189
(matching shares)
|
||
£15.275
|
127.067
(matching shares)
|
||
£15.275
|
83.594
(matching shares)
|
||
£15.275
|
170.189
(matching shares)
|
||
£15.275
|
127.067
(matching shares)
|
||
d)
|
Aggregated
information
Aggregated
volume
Price
|
1,523.426
£15.275
|
|
e)
|
Date
of the transaction
|
2017-10-12
|
|
f)
|
Place
of the transaction
|
n/a
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
a)
|
Name
|
Mr P C Thomson
|
|
b)
|
Position/status
|
President, Global Affairs
|
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
|
b)
|
Nature
of the transaction
|
Increase in notional interest in Ordinary Shares following the
re-investment of dividends paid to shareholders on 12 October 2017
on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus
Plan.
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
£15.275
|
56.787
(personal contribution)
|
||
£15.275
|
104.127
(personal contribution)
|
||
£15.275
|
79.994
(personal contribution)
|
||
£15.275
|
56.787
(matching shares)
|
||
£15.275
|
104.127
(matching shares)
|
||
£15.275
|
79.994
(matching shares)
|
||
d)
|
Aggregated
information
Aggregated
volume
Price
|
481.816
£15.275
|
|
e)
|
Date
of the transaction
|
2017-10-12
|
|
f)
|
Place
of the transaction
|
n/a
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
a)
|
Name
|
Mr D E Troy
|
|
b)
|
Position/status
|
SVP & General Counsel
|
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
a)
|
Description
of the financial instrument
|
American Depositary Shares ('ADSs')
ISIN: US37733W1053
|
|
b)
|
Nature
of the transaction
|
Increase in notional interest in ADSs following the re-investment
of dividends paid to shareholders on 12 October 2017 on ADSs held
in the Company's 2009 Deferred Annual Bonus Plan.
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
$41.020
|
43.227
(personal contribution)
|
||
$41.020
|
97.329
(personal contribution)
|
||
$41.020
|
80.611
(personal contribution)
|
||
$41.020
|
43.227
(personal contribution)
|
||
$41.020
|
97.329
(personal contribution)
|
||
$41.020
|
80.599
(personal contribution)
|
||
$41.020
|
43.227
(matching shares)
|
||
$41.020
|
97.329
(matching shares)
|
||
$41.020
|
80.611
(matching shares)
|
||
$41.020
|
43.227
(matching shares)
|
||
$41.020
|
97.329
(matching shares)
|
||
$41.020
|
80.599
(matching shares)
|
||
d)
|
Aggregated
information
Aggregated
volume
Price
|
884.644
$41.020
|
|
e)
|
Date
of the transaction
|
2017-10-12
|
|
f)
|
Place
of the transaction
|
n/a
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
a)
|
Name
|
Dr P J T Vallance
|
|
b)
|
Position/status
|
President,
R&D
|
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
|
b)
|
Nature
of the transaction
|
Increase in notional interest in Ordinary Shares following the
re-investment of dividends paid to shareholders on 12 October 2017
on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus
Plan.
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
£15.275
|
123.070
(personal contribution)
|
||
£15.275
|
200.197
(personal contribution)
|
||
£15.275
|
138.016
(personal contribution)
|
||
£15.275
|
123.070
(personal contribution)
|
||
£15.275
|
200.197
(personal contribution)
|
||
£15.275
|
138.016
(personal contribution)
|
||
£15.275
|
123.070
(matching shares)
|
||
£15.275
|
200.197
(matching shares)
|
||
£15.275
|
138.016
(matching shares)
|
||
£15.275
|
123.070
(matching shares)
|
||
£15.275
|
200.197
(matching shares)
|
||
£15.275
|
138.016
(matching shares)
|
||
d)
|
Aggregated
information
Aggregated
volume
Price
|
1,845.132
£15.275
|
|
e)
|
Date
of the transaction
|
2017-10-12
|
|
f)
|
Place
of the transaction
|
n/a
|
|
GlaxoSmithKline plc
|
|
(Registrant)
|
|
|
Date: October
16, 2017
|
|
|
|
|
By: VICTORIA
WHYTE
--------------------------
|
|
|
|
Victoria Whyte
|
|
Authorised
Signatory for and on
|
|
behalf
of GlaxoSmithKline plc
|